Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
EPIROC AB SPON ADS CL B EACH REP 1 COM (EPOBY) is trading at $21.48, flat on the day. Its market value of $25.98B makes it the 760th largest of the 2132 companies we follow.
The 52-week range is $18.47 to $23.00. Today's price is about 66% of the way from the low to the high. Holders are ahead 13.9% over twelve months, but down 6.6% across the last three months.
Price is below the 50-day average ($21.56) but above the 200-day ($19.57); RSI is 35, and the last 30 sessions moved at roughly 16% annualized volatility.
Valuation works out to 27.5 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 2132 U.S. stocks BeStock covers.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
EPOBY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.3% | Bearish |
| Price vs 50-day average | -0.4% | Bearish |
| Price vs 200-day average | +9.8% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 34.7 | Bearish |
| MACD (12,26,9) | -0.12 | Bearish |
| Bollinger band position | 36% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 9:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 2,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$21.48 is the latest print for EPOBY, a move of +0.00% against yesterday's close of $21.48. Today's low and high so far: $22.83 and $22.83.
Equity value comes to $25.98B at the current price. By that measure it is number 760 of the 2132 names in our coverage.
Buyers pay 27.5 times the last twelve months of profit (EPS $0.78).
The year's floor is $18.47 and the ceiling $23.00. Shares are 6.6% away from that ceiling.
It does. Payouts over the past twelve months work out to a 1.89% yield.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on EPOBY.